Detalles del Artículo
Detalles del Artículo

< Ant.
Sig. >
 
Título Artículo Self-paced timing detects and tracks change in prodromal Huntington diseaseArtículo de Revista
Parte de Neuropsychology
Vol. 24, n. 4 (Jul. 2010)
Pagina(s) 435-442
Idioma Inglés;
Materia(s) Cognición;
Nota(s) Autores: Rowe, Kelly C.; Paulsen, Jane S.; Langbehn, Douglas R.; Duff, Kevin; Beglinger, Leigh J.; Wang, Chiachi; O'Rourke, Justin J. F.; Stout, Julie C.; Moser, David J
Resumen Objective: This study compares self-paced timing performance (cross-sectionally and longitudinally) between participants with prodromal Huntington's disease (pr-HD) and a comparison group of gene non-expanded participants from affected families (NC). Method: Participants (747 pr-HD: 188 NC) listened to tones presented at 550-ms intervals, matched that pace by tapping response keys and continued the rhythm (self-paced) after the tone had stopped. Standardized cross-sectional and longitudinal linear models examined the relationships between self-paced timing precision and estimated proximity to diagnosis, and other demographic factors. Results: Pr-HD participants showed significantly less timing precision than NC. Comparison of pr-HD and NC participants showed a significant performance difference on two task administration conditions (dominant hand: p < .0001; alternating thumbs: p < .0001). Additionally, estimated proximity to diagnosis was related to timing precision in both conditions, (dominant hand: t = -11.14, df = 920, p < .0001; alternating thumbs: t = -11.32, df = 918, p < .0001). Longitudinal modeling showed that pr-HD participants worsen more quickly at the task than the NC group, and rate of decline increases with estimated proximity to diagnosis in both conditions (dominant hand: t = -2.85, df = 417, p = .0045; alternating thumbs: t = -3.56, df = 445, p = .0004). Effect sizes based on adjusted mean annual change ranged from -0.34 to 0.25 in the longitudinal model. Conclusions: The self-paced timing paradigm has potential for use as a screening tool and outcome measure in pr-HD clinical trials to gauge therapeutically mediated improvement or maintenance of function. (PsycINFO Database Record (c) 2010 APA, all rights reserved)
Objetos Asociados Ver libro electrónico